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Abstract  23 
Interferon lambda 4 (IFNL4) is a recently identified enigmatic member of the 24 
interferon lambda family. Genetic data suggest that the IFNL4 gene acts in a pro-viral 25 
and anti-inflammatory manner in patients. However, the protein is in vitro 26 
indistinguishable from the other members of the interferon lambda family. We have 27 
investigated the gene regulation of IFNL4 in detail and found that it differs radically 28 
from that of canonical antiviral interferons. Being induced by viral infection is a 29 
defining characteristic of interferons, but viral infection or overexpression of 30 
members of the interferon regulatory factor (IRF) family of transcription factors only 31 
leads to a minute induction of IFNL4. This behavior is evolutionarily conserved and 32 
can be reversed by inserting a functional IRF3 binding site into the IFNL4 promoter. 33 
Thus, the regulation of the IFNL4 gene is radically different and might explain some 34 
of the atypical phenotypes associated with the IFNL4 gene in humans. 35 
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Importance 45 
Recent genetic evidence has highlighted how the IFNL4 gene acts in a 46 
counterintuitive manner as patients with a non-functional IFNL4 gene exhibit 47 
increased clearance of hepatitis C virus  but also increased liver inflammation. This 48 
suggests that the IFNL4 gene acts in a pro-viral and anti-inflammatory manner. Those 49 
surprising but quite clear genetic data have prompted an extensive examination of the 50 
basic characteristics of the IFNL4 gene and its gene product IFN-λ4. We have 51 
investigated the expression of the IFNL4 gene and found it to be poorly induced by 52 
viral infections. A thorough investigation of the IFNL4 promoter revealed a highly 53 
conserved and functional promoter, but also one that lacks the defining characteristic 54 
of IFNs, i.e. the ability to be effectively induced by viral infections. We suggest that 55 
the unique function of the IFNL4 gene is related to its non-canonical transcriptional 56 
regulation. 57 
 58 
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 67 
Introduction  68 
Interferons (IFNs) are divided into three families according to their distinct receptor 69 
utilization: type I (e.g. IFN-α/β,), type II (IFN-γ) and type III (IFN-λ). Both type I and 70 
type III IFNs are potent antiviral cytokines (1).  Type II IFN also possesses some 71 
antiviral effect but its primary function is to link the innate and adaptive parts of the 72 
immune system (2). Type I and type III IFNs play a key role in innate immunity 73 
towards viral infection and their expression is induced by viral infection in both 74 
immune and non-immune cells (3-5). Humans possess four type III IFN genes known 75 
as IFNL1, IFNL2, IFNL3 and IFNL4. IFNL1-3 share a high degree of similarity and 76 
were identified as a novel family of genes encoding virally induced IFNs by two 77 
independent teams in 2003 (6, 7). In the following decade, genome-wide association 78 
studies linked clearance of hepatitis C virus (HCV) to genetic variation within the 79 
type III IFN loci (8-11), and this subsequently led to the discovery of the IFNL4 gene 80 
when genetic data was compared with RNA-sequencing analysis (12). The DNA 81 
sequence similarity between the IFNL4 gene and the IFNL1-3 genes is relative low 82 
and at the protein level the identity is approximately 28% (13). The IFNL4 gene is 83 
well conserved among mammals, except in rodents where the gene is absent.  84 
Upon identification of the IFNL4 gene, the authors also identified a dinucleotide 85 
variant (ΔG/TT, rs368234815) situated in the first exon of the IFNL4 gene (12). The 86 
IFNL4-TT frameshift mutation was introduced during early human evolution, before 87 
the “out of Africa” scenario (14). There has subsequently been a positive selection for 88 
the IFNL4-TT allele resulting in this being the major allele in humans, but with major 89 
variations in allele frequency between different human populations. The ΔG/TT 90 
variation is associated with the rate of spontaneous HCV clearance as well as the 91 
 on January 9, 2020 at U
niversitaetsbibliothek B
ern
http://jvi.asm
.org/
D
ow
nloaded from
 
response to treatment (12). The IFNL4-ΔG is the ancestral allele and generates the 92 
full-length IFN-λ4 protein, whereas the IFNL4-TT allele leads to a frameshift and 93 
therefore aborted expression of IFN-λ4. Surprisingly, patients harboring the 94 
functional IFNL4-ΔG allele have a lower HCV clearance rate compared to those 95 
patients, who have the IFNL4-TT allele (12). Interestingly, the IFNL4-ΔG allele is 96 
also associated with lower liver inflammation and fibrosis in HCV-infected patients 97 
(15-17) as well as patients with non-alcoholic fatty liver disease (18, 19). Thus, the 98 
genetic evidence suggests that in vivo, the IFNL4 gene acts in a pro-viral and anti-99 
inflammatory manner, quite in contrast to the pro-inflammatory and anti-viral effect 100 
of other type III IFNs. Here, we will use the term canonical IFNs about all type I and 101 
type III IFN genes, except IFNL4.  102 
Biochemically, the IFN-λ4 protein acts in a manner similar to the proteins encoded by 103 
the canonical type III IFN genes. It signals through the canonical IFN-λ receptor 104 
complex (20) and induces a set of genes highly similar to that induced by the 105 
canonical members of the IFN-λ family (20, 21). Despite its clear antiviral activity in 106 
vitro, the causal role of the IFN-λ4 protein in lower HCV clearance rates is supported 107 
by the finding that a single amino acid substitution of a proline to a serine at position 108 
70 (IFN-λ4 P70S) in IFN-λ4 substantially affects the antiviral activity of the protein 109 
(22). HCV patients harboring the impaired IFN-λ4 S70 variant display lower IFN-110 
stimulated gene (ISG) expression levels but better treatment response rates and better 111 
spontaneous clearance rates, when compared to patients coding for the fully active 112 
IFN-λ4 P70 variant (22). Finally, comprehensive genome-to-genome analysis in 113 
chronically infected HCV patients supported a role for the IFNL4 gene as the 114 
causative gene. In this study, IFNL4 genotype determined viral load and affected the 115 
evolution of HCV quasispecies within patients (23). Thus, the result is a paradox 116 
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where the IFN-λ4 protein is antiviral in vitro but appears to be “pro-viral” and “anti-117 
inflammatory” in vivo.  118 
Several attempts have been made to measure induction of the IFNL4 gene during viral 119 
infection, both in vivo and in vitro. Expression of IFNL4 mRNA was not detected in 120 
peripheral blood mononuclear cells from chronically infected HCV patients (24). 121 
Similarly, several other studies measured either no or very low IFNL4 mRNA 122 
expression in liver samples from patients with either non-viral liver diseases, chronic 123 
hepatitis B virus infection or chronic HCV infection (25-27). Finally, both stimulation 124 
with pathogen-associated molecular patterns (PAMP) and viral infection of different 125 
hepatoma cell lines or primary human hepatocytes resulted in minimal expression of 126 
IFNL4 but strong expression of the canonical IFNL3 (28). Together these 127 
observations led to speculation that the IFNL4 promoter is non-functional and that this 128 
is part of a general trend during human evolution to abrogate expression of the IFN-λ4 129 
protein.   130 
It is currently unclear why the IFN-λ4 protein became a liability in humans, whereas 131 
it is retained in most other mammalian species. To explain the unique genetic 132 
observations linked to the IFNL4 gene, we searched for characteristics of the IFNL4 133 
gene that differentiates it from the canonical IFNs. Here, we demonstrate that the 134 
IFNL4 promoter is indeed functional and that the mode of gene regulation differs 135 
substantially between the IFNL4 gene and canonical IFNs. Furthermore, we show that 136 
the unique features of the IFNL4 promoter are evolutionarily conserved.  137 
 138 
Results  139 
Expression of IFNL4 mRNA is negligible upon viral infection in different human 140 
cell types. The expression of most IFNs is rapidly induced following a viral infection. 141 
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Upon infection of human A549 cells with Sendai virus (SeV), expression of IFNL1 142 
mRNA increased more than 100,000-fold within 5 - 6 hours before it appeared to 143 
reach a plateau (Fig. 1A). The expression of IFNL4 mRNA also increased 144 
significantly within the first 5 - 6 hours of infection but far less than that of IFNL1. At 145 
8 hours after infection, the expression level of IFNL4 appeared to reach a plateau and 146 
was 300-fold lower than for IFNL1. To further investigate the rather low expression 147 
level of IFNL4 mRNA, we compared the expression of this gene as well as IFNL1 and 148 
IFNB1 in four different human cell lines with or without viral infection. Based on the 149 
earlier results, we chose to measure mRNA levels at 6 hours after infection or mock-150 
infection. As expected, infection with SeV led to a robust expression of IFNB1 and 151 
IFNL1 mRNA in A549, THP-1 and PC-3 cells and a moderate expression of IFNL1 152 
but not IFNB1 in HepG2 cells (Fig. 1B). In contrast, the expression of IFNL4 was 153 
much lower than that of the two canonical IFNs and even after viral infection, 154 
expression of IFNL4 rarely exceeded the baseline expression of IFNB1 and IFNL1. 155 
With the exception of the HepG2 cells, the absolute expression of IFNB1 and IFNL1 156 
was a 1000-fold higher than that of IFNL4 following viral infection. Of note, in both 157 
A549 and HepG2 cells, the IFNL1 and IFNL4 mRNA levels were close to the 158 
detection limit in the absence of viral infection, and for several of the replicates, no 159 
product was detected within 40 cycles and those measuring points were thus omitted 160 
(Fig. 1B). Cell lines sometimes exhibit minor or major defects in innate immune 161 
pathways and therefore we tested the expression of IFNL4 mRNA in primary human 162 
airway epithelial cell (hAEC) cultures stimulated with poly(I:C) and compared it to 163 
that of IFNB1 and IFNL1 mRNAs (Fig. 1B). In these cells, poly(I:C) stimulation led 164 
to a robust expression of IFNL1 mRNA whereas IFNB1 mRNA levels were relatively 165 
high even in the absence of poly(I:C) and did not increase further after poly(I:C) 166 
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treatment. In contrast, IFNL4 mRNA levels were below the detection limit both with 167 
and without poly(I:C) stimulation. 168 
The overall low expression of IFNL4 mRNA was surprising to us because a 169 
substantial expression of the IFNL4 gene was previously reported to occur in 170 
epithelial cells infected by human metapneumovirus (hMPV) (29). Therefore, we 171 
repeated this experiment where we measured induction of IFNLs transcripts in A549 172 
cells infected by an influenza A virus (IAV) variant lacking its NS1 gene (IAV ΔNS1), 173 
or by hMPV. In contrast to previously published data, hMPV infection did not lead to 174 
any substantial expression of IFNL4 mRNA in our experiments but did induce the 175 
expression of IFNL1 mRNA (Fig. 1C). As expected, infection with IAV ΔNS1 176 
resulted in a strong induction of IFNL1 mRNA but only a minor induction of IFNL4 177 
mRNA. Altogether, IFNL4 expression is negligible compared to that of IFNL1 in 178 
A549 cells after hMPV or IAV ΔNS1 infection (Fig. 1C). This leads us to suggest that 179 
IFNL4 is a non-canonical IFN as it lacks the otherwise defining characteristic of IFNs, 180 
i.e. their strong induction upon viral infection.  181 
 182 
The IFNL1 but not the IFNL4 promoter is activated by viral infection or 183 
overexpression of MAVS. To create a system which allowed us to characterize the 184 
IFNL4 promoter in detail, we cloned a 2,186 bp fragment of the IFNL1 promoter and 185 
a 2,387 bp fragment of the IFNL4 promoter in front of a firefly luciferase gene (Fig. 186 
2A). Because IFN regulatory factor 3 (IRF3) is a crucial transcription factor 187 
governing expression of canonical IFNs, we used two ways of activating IRF3: 188 
overexpression of the adaptor protein MAVS, which signals upstream of IRF3, or 189 
infection with SeV. First, HEK293T cells were transfected with either the IFNL1 or 190 
IFNL4 promoter reporter construct along with increasing amounts of a construct 191 
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encoding MAVS (Fig. 2B). The results show that the IFNL1 promoter is potently 192 
induced by MAVS overexpression whereas this is not the case for the IFNL4 193 
promoter. Even at the highest amount of MAVS-encoding construct used, the IFNL1 194 
promoter gives an approximately 230-fold stronger luciferase activity than the IFNL4 195 
promoter. Next, we repeated the experiment using SeV infection instead of 196 
overexpression of MAVS, with the similar result that the IFNL1 but not the IFNL4 197 
promoter was potently induced by SeV infection (Fig. 2C). This is consistent with the 198 
previous results showing a very low IFNL4 mRNA expression level in human cell 199 
lines. 200 
 201 
The IFNL1 but not the IFNL4 promoter is activated by IRF3 and IRF7 following 202 
SeV infection. The transcription factors IRF3 and IRF7 both play an important role in 203 
controlling expression of canonical IFNs. However, they are member of a larger 204 
family consisting of nine members, IRF1-9. It is possible that activation of the IFNL4 205 
promoter requires other members of the IRF family than those needed for expression 206 
of the canonical IFNs. Therefore, we transfected expression constructs encoding the 207 
different IRF members into IRF3 knock out HEK293T cells together with either the 208 
IFNL4 or the IFNL1 promoter reporter construct and then infected the cells with SeV 209 
before measuring luciferase activity. Overexpression of both IRF3 and IRF7 led to a 210 
small, yet significant induction of the IFNL4 promoter upon virus stimulation. 211 
However, this induction is negligible compared to that of the IFNL1 promoter (Fig. 212 
2D) and underlines the unique regulatory requirement of the IFNL4 promoter. In 213 
contrast, the IFNL1 promoter was induced by both IRF3 and IRF7 as expected (Fig. 214 
2E).  215 
 216 
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Is the behavior of the IFNL4 promoter evolutionarily conserved?  217 
The above experiments showed that the human IFNL4 promoter is functionally 218 
different from the human IFNL1 promoter. However, since there has been a selection 219 
against a functional IFNL4 gene in humans (SNP ΔG/TT, rs368234815), it is possible 220 
that low IFNL4 promoter activity is a result of an evolutionary pressure to reduce 221 
IFNL4 expression. If this is the case, the low activity of the IFNL4 promoter should 222 
be specific to humans as the selection against an active form of the IFNL4 gene 223 
(ΔG/TT, rs368234815) is a recent event in human evolution (14). To investigate this, 224 
we tested the expression of IFNL4 mRNA in pigs as well as the activity of IFNL4 225 
promoters from several mammalian species. We used primary porcine airway 226 
epithelial cell cultures stimulated with poly(I:C) and measured IFNL2 and IFNL4 227 
mRNA levels by semi-quantitative PCR (Fig. 3). The expression of the porcine IFNL2 228 
gene is clearly induced by poly(I:C) after 30 cycles whereas IFNL4 specific primers 229 
only yielded a faint band after 40 cycles, indicating a rather low expression of IFNL4 230 
following poly(I:C) stimulation. This suggests that the difference in expression of 231 
IFNL4 compared to that observed for canonical IFNs is not unique to humans and 232 
accordingly seems not to be the result of the recent selection against a functional 233 
IFNL4 gene in humans.  234 
This observation prompted us to investigate the activity of the IFNL4 promoter from a 235 
number of mammalian species. The leucine rich repeat and fibronectin type III 236 
domain containing 1 (LRFN1) and syncollin (SYCN) genes, which flank each side of 237 
the type III IFN loci, are evolutionarily conserved among mammals (Fig. 4A). We 238 
used those genes to mark the borders of the type III IFN loci and then analyzed the 239 
genomic loci in a number of mammalian species to identify IFNL4 orthologues. We 240 
analyzed the genomic loci from human, African green monkey, sheep, pig and the 241 
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house mouse because in these species the type III IFN loci are fully sequenced. The 242 
IFNL1 gene is present in humans and African green monkey but is absent in sheep, 243 
mouse, and pig, whereas the IFNL2 and/or IFNL3 genes can be found in all five 244 
species (Fig. 4A). Many mammals seem to have two highly similar IFNL4 genes, but 245 
in humans, one of these IFNL4 genes has become a pseudogene whereas mice have 246 
no IFNL4 genes. As for sheep and pigs, sheep possess two IFNL4 genes like many 247 
other ungulates while pigs only possess one IFNL4 gene. Thus, humans and pigs have 248 
a single IFNL4 gene while African green monkeys and sheep have two IFNL4 genes. 249 
We performed an evolutionary analysis of the IFNL4 genes we identified and 250 
concluded that independent duplications of the IFNL4 gene must have occurred 251 
several times during mammalian evolution. This makes it difficult to precisely 252 
destinguish between true paralouges and ortologues genes and we therefore chose 253 
those IFNL4 genes which had the same orientation as the human IFNL4 gene for our 254 
investigation. 255 
To describe if the functionality of the IFNL4 promoter is evolutionary conserved, we 256 
cloned the IFNL4 promoters from African green monkey, sheep and pig and added 257 
them to our comparison. As a control, we also cloned the IFNL2 or IFNL3 promoter 258 
from these species, except from African green monkey where it was not possible due 259 
to technical limitations. To compare the different IFNL4 promoters, HEK293T cells 260 
were transfected with the different type III IFN promoter reporter constructs along 261 
with a construct encoding MAVS (Fig. 4B). Our comparison showed that the IFNL4 262 
promoter is induced to a much lower degree by overexpression of MAVS than the 263 
IFNL1/IFNL2/IFNL3 promoters in all four species that we have tested here. The same 264 
results are also seen when we stimulated cells with SeV infection instead of MAVS 265 
overexpression (Fig. 4C). One concern by using non-human promoters in HEK293T 266 
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cells is the compatibility of those promoters with the human system. However, we 267 
consistently saw strong induction of the IFNL1/IFNL2/IFNL3 genes and furthermore 268 
the data from the primary pig airway epethelial cells was in agreement with the data 269 
obtained using the pig promoters in the HEK293T cells. Altogether, the results 270 
suggest that the behavior of the IFNL4 promoter appears to be a conserved among 271 
mammals.  272 
 273 
The IFNL4 promoter is highly conserved and forms a separate evolutionary 274 
clade. The evolutionarily conserved behavior of the IFNL4 promoter prompted us to 275 
examine the degree of sequence conservation within the IFNL4 promoter region. 276 
Figure 5A shows a nucleotide alignment of the first 600 base pairs (bp) of the IFNL4 277 
promoters, counting from the translational start site, from those species examined in 278 
the previous promoter activity assay. We chose the translational start site to anchor 279 
this alignment for two reasons: i) it is clearly defined for all species and ii) regulatory 280 
elements can be found both upstream and downstream of the transcriptional start site. 281 
The analysis demonstrated a high degree of conservation suggesting that there has 282 
been a significant selective pressure on this region throughout mammalian evolution.   283 
Next, we calculated an evolutionary tree from a set of IFNL4 and IFNL1 promoter 284 
sequences. The promoter sequences form two clearly separated clades according to 285 
which genes they belong to, confirming our previous conclusion that the IFNL4 286 
promoter is both evolutionary and functional distinct from the canonical IFN 287 
promoters (here represented by the IFNL1 promoter) (Fig. 5B). We also calculated a 288 
tree based upon the protein sequences of IFN-λ1 and IFN-λ4 from the same set of 289 
species, and as previously observed (3), the IFN-λ4 sequences form a separate and 290 
distinct clade  (Fig. 5C). 291 
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The basic IFNL4 promoter is functional and can be activated by an enhancer 292 
element present in the IFNL1 promoter. A promoter region can, somewhat 293 
simplified, be described as consisting of a core promoter where the RNA polymerase 294 
II complex assembles, and a series of upstream and/or downstream regulatory 295 
elements. To test if the core promoter of IFNL4 is functional, we constructed chimera 296 
A combining 100 bp of proximal IFNL4 promoter and upstream 1,989 bp of IFNL1 297 
promoter (Fig 6A). Chimera A is active upon overexpression of MAVS, whereas the 298 
inverse chimera B with the IFNL1 core promoter fused to the upstream regulatory 299 
elements of the IFNL4 promoter was largely inactive, indicating that the IFNL4 core 300 
promoter can be activated by enhancer elements present in the IFNL1 promoter. To 301 
determine if the IRF binding site of the IFNL1 promoter functions as an enhancer in 302 
the context of the IFNL4 promoter, we constructed chimera C. In chimera C, the IRF 303 
binding motif from the IFNL1 promoter was inserted into the IFNL4 promoter in the 304 
same position as it occupies in IFNL1 promoter, which is 100 bp upstream of the 305 
transcription start site (TSS) (Fig 6B). Chimera C is active whereas chimera C with a 306 
mutated IRF site (mutIRF) is inactive (the IRF binding site was mutated by changing 307 
nucleotides CAGTTTC of this motif into AAGCAGA). Thus, by inserting a 308 
functional IRF binding site into context of the IFNL4 promoter, the promoter becomes 309 
inducible by viral infection. These results confirm that the IFNL4 promoter is a 310 
potentially functional core promoter sequence.  311 
 312 
A non-functional and out of place IRF binding site is found within the IFNL4 313 
promoter. Above, we demonstrated that insertion of the IRF site from the IFNL1 314 
promoter into the IFNL4 promoter resulted in a virus-inducible activation of the 315 
IFNL4 promoter. However, one putative IRF site exists within the IFNL4 promoter. 316 
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Replacing the canonical IRF site found in the IFNL1 promoter with the putative IRF 317 
binding site from the IFNL4 promoter resulted in chimera D (Fig. 6C). Chimera D 318 
exhibited only minimal activity upon MAVS overexpression implying that the IRF 319 
binding site of IFNL4 is not functional within the context of the IFNL1 promoter. Not 320 
only does the sequence of the IRF binding sites differ between the IFNL1 and IFNL4 321 
promoters but their positions differ as well. While the IRF binding site in the IFNL1 322 
promoter is located relatively close to the TSS (100 bp from the TSS), the IRF 323 
binding site in the IFNL4 promoter is located further upstream (224 bp from the TSS). 324 
This is more distant to the TSS compared to most canonical IFN promoters. In 325 
chimera E, we inserted the IRF motif of the IFNL1 promoter into the position of the 326 
putative IRF binding site already found within the IFNL4 promoter. Thus, chimera C 327 
and E differ only by the position of the inserted IRF binding site, yet only chimera C 328 
is activated by MAVS overexpression, which shows that the position of the IRF 329 
binding site does matter (Fig. 6C). In conclusion, whereas the IFNL4 promoter 330 
contains a putative IRF binding site this seems to be non-functional.  331 
  332 
The IFNL4 promoter contains functional NF-κB sites. Efficient induction of IFN 333 
normally requires collaboration between the transcription factors IRF3 and NF-κB 334 
and we therefore searched for NF-κB binding sites at the proximal end of the IFNL4 335 
promoter. Two such sites were identified. To test if these sites potentially could be 336 
involved in conferring transcriptional activity, we mutated them individually or 337 
together in context of the transcriptionally active chimera C (Fig. 6D). Both mutNF-338 
κB1 and mutNF-κB1/2 have reduced transcription whereas mutNF-κB2 has a minimal 339 
effect (Fig. 6D). This indicates that the NF-κB1 site is required for transcriptional 340 
activity of chimera C, whereas the NF-κB2 site is less important.  341 
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 342 
Both IRF3 and RNA polymerase II are recruited to the IFNL4 promoter in 343 
response to viral infection. To investigate if the IRF3 transcription factor and RNA 344 
polymerase II are recruited to the promoter of IFNL1 and IFNL4, we performed 345 
chromatin immune precipitation (ChIP) assays on A549 cells infected by SeV. For 346 
this purpose, we used antibodies against IRF3 and RNA polymerase II as well as IgG 347 
as a control (Fig. 7A-C). The data show that IRF3 is recruited to the promoter region 348 
of both IFNL1 and IFNL4 but with a tendency towards lower enrichment of IRF3 on 349 
the IFNL4 promoter region after virus infection as compared to IFNL1 (Fig. 7A). 350 
Moreover, we found that RNA polymerase II occupies both promoters after SeV 351 
infection but more RNA polymerase II was detected at the IFNL1 promoter (Fig. 7B). 352 
Thus, decreased IRF3 and RNA polymerase II recruitment can account for at least 353 
some of the low response to viral infection exhibited by the IFNL4 promoter as 354 
compared to the IFNL1 promoter.  355 
 356 
Discussion 357 
Genetic data has attributed unique properties to the IFNL4 gene. It protects against 358 
liver fibrosis (17, 19) and hence it is assumed to help dampening or controlling 359 
inflammation in both HCV infected patients and patients with non-alcoholic steatosis 360 
(NASH) (15). Furthermore, its ablation facilitates both spontaneous and treatment-361 
induced HCV clearance (12). These observations are counterintuitive when taking 362 
into account that IFNs are normally both antiviral and pro-inflammatory and suggest 363 
that the IFNL4 gene is functionally distinct from the canonical IFNs. We have 364 
conducted a series of experiments to biochemically characterize the IFN-λ4 protein, 365 
but found that the biochemical properties of the IFN-λ4 protein are highly similar to 366 
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those of other members of the IFN-λ family, i.e. the IFN-λ4 protein signals through 367 
the same receptor and induces a set of genes highly similar to that induced by the 368 
IFN-λ3 protein (20, 21).  369 
A defining characteristic of IFNs is their ability to be induced by viral infection 370 
through the transcription factors IRF3 or IRF7 (30). Here we demonstrate that while 371 
the IFNL4 gene has a putative IRF3/7 binding site, this site is either non-functional or 372 
functions very poorly resulting in little or no transcription of the IFNL4 gene in 373 
response to viral infections. This agrees well with previous data showing very low 374 
levels of IFNL4 mRNA in the liver of HCV infected patients (25) but contradicts 375 
other findings claiming that IFNL4 mRNA expression is induced by viral infection in 376 
vitro (29, 31).  377 
A previously published study showed that hMPV infection led to a strong induction 378 
(approximately 40,000-fold) of IFNL4 mRNA expression in A549 cells when 379 
compared to non-infected cells (29). However, when we tested IFNL4 gene 380 
expression in hMPV infected A549 cells, we found that the IFNL4 expression was 381 
weak and much lower than IFNL1 expression under the same conditions. A different 382 
study showed induction of the IFNL4 mRNA, measured as fold induction, in SeV 383 
infected PC-3 cells (31). We measured IFNL4 mRNA levels in PC-3 cells under 384 
similar conditions and although there was an induction of the IFNL4 mRNA in 385 
infected versus non-infected cells, the expression level was low and comparable to the 386 
level of IFNL1 mRNA found prior to viral infection. During a virus infection, large 387 
amounts of canonical IFNs are produced and in that context the rather marginal 388 
IFNL4 expression upon viral infection is unlikely to have significant role. Hence, we 389 
do not believe that the low level of IFNL4 mRNA produced by PC-3 or A549 cells is 390 
of physiological relevance.  391 
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We performed a series of assays on different IFNL4/IFNL1 promoter chimeras using a 392 
luciferase reporter system in HEK293 cells. Those data clearly show that inserting a 393 
functional IRF3 site at the proper position renders the IFNL4 promoter virus-inducible. 394 
We speculate that the IFNL4 promoter is regulated by yet unknown stimuli, and the 395 
evolutionary conservation of both the sequence of the IFNL4 promoter region as well 396 
as its functional characteristics supports this. Our efforts to identify such a stimulus 397 
has so far been in vain, but our preliminary data suggest that neither ER stress, LPS 398 
nor activation of the inflammasome leads to activation of the IFNL4 gene.  399 
Other examples of non-canonical regulation of IFN genes exist. The IFNE gene, in 400 
contrast to the other type I IFN genes, is not induced by viral infection but is 401 
specifically expressed in the female reproductive tract where it protects against 402 
infection. Furthermore, the expression of the IFNE gene is regulated by estrogen (32).   403 
To sum up, we conclude that the regulation of the IFNL4 gene is a conserved feature 404 
among mammals and that the IFNL4 gene is a non-canonical member of the type III 405 
IFN family as it is regulated in a unique way that differs from that of the canonical 406 
IFNs.  407 
 408 
Materials and methods 409 
Cells  410 
Cell lines used in this study were PC-3 (prostate cancer cell line), A549 (human lung 411 
epithelial cells), HepG2 (liver hepatocellular carcinoma), THP-1 (human monocytic 412 
cells) and IRF3 knock out HEK293T cells (human embryonic kidney cells). PC-3 413 
cells were cultured in F12K medium supplemented with 2 mM L-glutamine, 10% 414 
fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin. THP-1 415 
cells were cultured in the RPMI-1640 medium supplemented with 10% FBS, 100 416 
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U/ml penicillin and 100 µg/ml streptomycin. All other cell lines were cultured in 417 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 100 418 
U/ml penicillin and 100 µg/ml streptomycin.  419 
Well-differentiated human airway epithelial cell cultures from three biological donors 420 
were isolated, established and maintained as previously described (33). Primary 421 
porcine tracheobronchial airway epithelial cells were isolated from post-mortem 422 
material obtained from SPF-pigs. Isolation of cells was performed with protease and 423 
DNase digestion and primary porcine tracheobronchial cells were cultured as 424 
previously described (33) but with a few modifications. For cellular differentiation, 425 
the human epidermal growth factor concentration was increased ten-fold in the air-426 
liquid interface medium, whereas retinoic acid was two-fold more concentrated. The 427 
epithelial layer was allowed to differentiate for at least four weeks prior to stimulation 428 
experiments. 429 
 430 
Plasmids  431 
The different promoter sequences used in this study were cloned from genomic DNA 432 
using standard cloning techniques. The sources were THP-1 cells for the human 433 
IFNL1 and IFNL4 promoters, Vero cells for the African green monkey IFNL4 434 
promoter, Texel sheep peripheral blood mononuclear cells for the sheep IFNL3 and 435 
IFNL4 and Göttingen minipig tissue for the pig IFNL2 and IFNL4 promoters. Because 436 
the transcriptional start site has not been experimentally verified for most of these 437 
genes, we chose to always include the 5’ UTR in the cloned sequence. The sequences 438 
were cloned into the multiple cloning site of the pGL3.1-Basic plasmid (Promega) 439 
and afterwards the remaining sequence between the inserted promoter sequence and 440 
the translational start site of the firefly luciferase gene was deleted by site-directed 441 
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mutagenesis. The different chimeras and mutants of the human IFNL1 and IFNL4 442 
promoters were constructed using standard cloning techniques and site-directed 443 
mutagenesis. In chimera A, nucleotides -1 to -100 of the IFNL1 promoter were 444 
replaced by nucleotides -1 to -100 of the IFNL4 promoter. In chimera A, nucleotides -445 
1 to -100 of the IFNL4 promoter were replaced by nucleotides -1 to -98 of the IFNL1 446 
promoter. In chimera C, nucleotides -101 to -132 of the IFNL4 promoter were 447 
replaced with -101 to -134 of the IFNL1 promoter. In chimera C (mutIRF), 448 
nucleotides -129 to -123 from the IFNL1 promoter in chimera were changed from 449 
CAGTTTC to AAGCAGA. In chimera D, nucleotides -117 to -132 of the IFNL1 450 
promoter were replaced with nucleotides -225 to -235 of the IFNL4 promoter. In 451 
chimera E, nucleotides -225 to -235 in the IFNL4 promoter were replaced with 452 
nucleotides -117 to -132 of the IFNL1 promoter. In chimera C (mutNF-κB1), 453 
nucleotides -69 to -66 of the IFNL4 promoter in chimera C was changed from ACCC 454 
to CCCT. In chimera C (mutNF-κB2), nucleotides 32 to 35 of the IFNL4 promoter in 455 
chimera C was changed from CCCA to GGGT. Chimera (mutNF-κB1/2) is a 456 
combination of the two previous chimeras.  457 
The plasmids used for expressing IRF2, -4 and -8 (pEF-IRF2, pSV-LS-IRF4 and 458 
pICSBP) were kind gifts from professor Takashi Fujita (Kyoto University, Japan) 459 
whereas the plasmids for expression of IRF3 and MAVS (pcDNA3-IRF3 #32713 and 460 
pEF-BOS-MAVS #27224) were from Addgene. The plasmids used for expressing 461 
IRF1, -5, -6 and -7 were constructed in our laboratory. The sequences of all plasmids 462 
used in this study were verified by Sanger sequencing (GATC Biotech) and detailed 463 
information about them is available upon request. 464 
 465 
Infections and stimulations 466 
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For qPCR assays, cells were seeded in 6-well tissue culture plates at a density of 467 
6x10
5
 per well. For the THP-1 cells, phorbol 12-myristate 13-acetate (PMA) was 468 
added to a final concentration of 100 nM to trigger differentiation into macrophages. 469 
After resting for 24 hours, the cells were infected with 40 HAU SeV (Cantell strain) 470 
per well for 6 hours. Infection of A549 cells with hMPV was performed as previously 471 
described (29). 472 
For luciferase assays, cells were infected 24 hours post transfection with 20 HAU SeV 473 
(Cantell strain) per well for 24 hours. 474 
For ChIP assays, cells were seeded in 150 mm tissue culture dishes at a density of 1 x 475 
10
7
 cells per dish. After resting for 24 hours, the cells were infected with 560 HAU 476 
SeV (Cantell strain) per dish for 4 hours.  477 
For qPCR and semi-qPCR, human or porcine airway epithelial cells were treated with 478 
10 µg/ml poly(I:C) via the basolateral surface for a duration of 18 hours prior to cell 479 
lysis and total RNA extraction. 480 
 481 
Quantitative real-time and semi-quantitative PCR 482 
Total RNA was extracted with the E.Z.N.A. Total RNA Kit I (Omega Bio Tek) 483 
according to the manufacturer’s instructions. The cDNA synthesis was performed 484 
with 0.5 µg RNA using RevertAid Reverse Transcriptase and random hexamer primer 485 
according to the manufacturer's instructions (ThermoFisher Scientific). The cDNA 486 
was quantified by qPCR using SYBR Green I (Roche) and a LightCycler 480 487 
Instrument II (Roche). The following primers were used: human IFNB1, forward 488 
ACGCCGCATTGACCATCTAT and reverse GTCTCATTCCAGCCAGTGCT; 489 
human IFNL1, forward TTCCAAGCCCACCACAACTG and reverse 490 
GTGACTCTTCCAAGGCGTCC, human IFNL4, forward 491 
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CGGCCTGCCTTGAGCTG and reverse GGGTTTGTGACGCCTCTTCT; human 492 
HPRT1, forward CCCTGGCGTCGTGATTAGTG and reverse 493 
CACCCTTTCCAAATCCTCAGC. The cycling parameters were 95°C for 10 min 494 
followed by 40 cycles of 95°C for 10 s, 60°C for 5 s and 72 °C for 4 s. The crossing 495 
points of the amplification curves were determined using the second derivative 496 
method on the LightCycler 480 Instrument II software 1.5 (Roche). The 497 
hypoxanthine-guanine phosphoribosyltransferase (HPRT1) gene was used as a 498 
reference gene. The level of mRNA was normalized against internal HPRT mRNA 499 
content. Relative mRNA levels of each target gene were calculated using the 500 
following formula: 2^-(Ct (target)-Ct (control)).  501 
 502 
 503 
Semi-quantitative PCR 504 
The following primers were used: human IFNL1, forward 505 
GGAAGCAGTTGCGATTTAGCC and reverse GACTCTTCCAAGGCGTCCCT; 506 
human IFNL4, forward TTGGCTTCCCTGACGTCTCT and reverse 507 
CTCTTCCTCGTAGCGGTCCC; pig IFNL2, forward 508 
GTCCCTCTTGGAGGACTGGA and reverse CTGAGCTGGGACACAGGC; pig 509 
IFNL4, forward GATGTCCGTCGCCTCTTGTA and reverse 510 
GCGTCTCTTCCTCATAGTGGT. The PCR was performed as described above for 511 
qPCR and run for 20, 30, or 40 cycles. The PCR products were run on a 1% agarose 512 
TBE gel with a GeneRuler 100 bp Plus DNA Ladder (ThermoFisher Scientific) 513 
 514 
Transfections 515 
For transfection, cells were seeded in 12-well tissue culture plates at a density of 516 
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4×10
5
 cells per well. After resting for 24 hours, and then transfected 24 hours later 517 
using polyethylenimine (PEI). For all transfections, a total of 2 µg plasmid was gently 518 
mixed with 6 µg PEI in a total volume of 200 µl and incubated 15 minutes at room 519 
temperature before adding it drop wise to the cells. The 2 µg plasmid always included 520 
50 ng plasmid constitutively expressing Renilla luciferase and 1,000 ng pGL3.1 521 
plasmid containing a type III IFN promoter. Unless otherwise stated, 400 ng plasmid 522 
expressing one of the IRFs or MAVS was included in those experiments that required 523 
expression of these proteins. To reach the desired total of 2 µg plasmid for each 524 
transfection, an empty pcDNA3.1 plasmid was added accordingly.   525 
 526 
Luciferase assays 527 
At 24 hours after transfection/infection, cells were lysed with Passive Lysis Buffer 528 
(Promega) and firefly and Renilla luciferase activity in the lysate was then measured 529 
using the Dual-Luciferase Reporter Assay System (Promega) according to the 530 
manufacturer’s instructions.  531 
  532 
Chromatin immunoprecipitation (ChIP) 533 
ChIP was performed as previously described (34). The antibodies used were Mouse 534 
IgG Isotype Control (ThermoFisher Scientific), IRF-3 (D83B9) Rabbit mAb (Cell 535 
Signaling), Mouse Anti-RNA polymerase II CTD repeat YSPTSPS antibody [8WG16] 536 
(abcam) and Rabbit Anti-Histone H3 antibody (abcam). The co-immunoprecipated 537 
DNA was quantified by qPCR as described above except that the cDNA synthesis 538 
step was omitted. The following primers were used: human IFNL1, forward 539 
TGAGGCCAGTTGGCTGAAAG and reverse GGAGCCTGATGAGGGAACAG; 540 
human IFNL4, forward TCAACACTACACAAGGGCTGG and reverse 541 
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CGGTTTCCAAATTGTCTCTGTCC; GAPDH, forward 542 
GCGTGTAAGGGTCCCCGTCCT, and reverse GTTCAACTGGGCACGCACCGA 543 
  544 
 545 
Alignments and phylogenetic trees 546 
All the sequences used for alignments and phylogenetic trees were extracted from the 547 
corresponding genomic reference sequences from NCBI. The accession numbers of 548 
these are   NC000019 (human), NC023647 (African green monkey), NC010448 549 
(domesticated pig), NC019471 (domesticated sheep), NW007907093 (polar bear) and 550 
NW006804147 (western European hedgehog). Sequences were aligned using 551 
ClustalW and phylogenetic trees were generated using the Neighbor-Joining method 552 
in MEGA7.  553 
 554 
Statistical analysis  555 
Statistical analysis was performed in GraphPad Prism 8.2.  556 
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Figure Legends 576 
Figure 1. Expression of the IFNL4 gene is not virus-inducible. (A) A549 (an 577 
adenocarcinomic alveolar basal epithelial cell line) cells were infected with SeV and 578 
the expression levels of IFNL4 and IFNL1 genes were quantified by RT-qPCR at the 579 
indicated time points. Data were calculated relative to internal expression of HPRT. 580 
The experiment was performed in biological triplicates and data are presented as 581 
scatter plot with mean ± SD (n=3). (B) A549, HepG2 (a hepatocellular carcinoma cell 582 
line), macrophage-like differentiated THP-1 (a monocyte-like cell line before 583 
differentiation), and PC-3 (a prostate cancer cell line) cells were mock-infected or 584 
infected with SeV for 6 hours while human airway epithelial cell (hAEC) cultures 585 
were mock-treated or treated with poly(I:C) for 18 hours. Expression levels of IFNB1, 586 
IFNL4 and IFNL1 genes were quantified by RT-qPCR. Data were calculated relative 587 
to internal expression of HPRT. The dashed line indicates the detection limit in those 588 
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cases where mRNA levels could not be determined for some replicates because they 589 
were too low. The experiment was performed in biological sextuplicates (left panel) 590 
or triplicates (right panel) and data are presented as scatter plot with mean ± SD (n=3 591 
or 6).  Statistical significance was determined using an unpaired t test. *, 0.01 < P < 592 
0.05; ns, P ≥ 0.05. (B) A549 cells were mock-infected or infected with hMPV or IAV 593 
ΔNS1 for 18 hours. Expression levels of IFNL1 and IFNL4 mRNA were assessed by 594 
semiquantitative PCR and vizualised by agarose gel electrophoresis. The experiment 595 
was performed in biological duplicates.  596 
 597 
Figure 2. The IFNL4 promoter is not activated by the same stimuli that readily 598 
activate the IFNL1 promoter. (A) The promoter regions of the human IFNL1 and 599 
IFNL4 genes corresponding to 2,186 and 2,387 bp, respectively, upstream of their 600 
translation start site were inserted in front of the firefly luciferase coding sequence in 601 
the pGL3.1-Basic plasmid. (B) HEK293T cells were co-transfected with pGL3.1 602 
plasmid containing the IFNL1 or IFNL4 promoter, a plasmid constitutively expressing 603 
the Renilla luciferase gene and increasing amounts of a plasmid expressing MAVS. 604 
At 24 hours post transfection, firefly/Renilla luciferase activity was quantified. The 605 
experiment was performed in biological triplicates and the data are presented as bar 606 
chart and scatter plot with mean ± SD (n=3). (C) HEK293T cells were co-transfected 607 
with pGL3.1 plasmid containing the IFNL1 or IFNL4 promoter and a plasmid 608 
constitutively expressing the Renilla luciferase gene. At 24 hours post transfection, 609 
the cells were infected with SeV for another 24 hours before quantifying 610 
firefly/Renilla luciferase activity. One representative out of two independent 611 
experiments is shown, each with biological triplicates. The data are presented as bar 612 
chart and scatter plot with mean ± SD (n=3). (D-E) IRF3 knock out HEK293T cells 613 
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were co-transfected with pGL3.1 plasmid containing the IFNL1 (D) or IFNL4 (E) 614 
promoter in front of a firefly luciferase gene, a plasmid constitutively expressing the 615 
Renilla luciferase gene and a plasmid constitutively expressing IRF1, IRF2, IRF3, 616 
IRF4, IRF5, IRF6, IRF7 or IRF8. At 24 hours post transfection, the cells were 617 
infected with SeV for another 24 hours before quantifying firefly/Renilla luciferase 618 
activity. One representative out of two independent experiments is shown, each with 619 
biological triplicates. The data are presented as bar chart and scatter plot with mean ± 620 
SD (n=3). Statistical significance was determined using an unpaired t test. ****; P < 621 
0.0001, ***, 0.0001 < P < 0.001; **, 0.001 < P < 0.01; *, 0.01 < P < 0.05; ns, P ≥ 622 
0.05. 623 
 624 
Figure 3. The IFNL4 gene is poorly expressed in primary porcine epithelial cells. 625 
Porcine airway epithelial cells (pAECs) were treated with 10 µg/ml poly(I:C) via the 626 
basolateral surface for 18 hours. Expression levels of IFNL2 and IFNL4 mRNA were 627 
assessed by semiquantitative PCR and vizualised by agarose gel electrophoresis. The 628 
experiment was performed in biological triplicates. 629 
 630 
Figure 4. The weak functionality of the IFNL4 promoter is evolutionary 631 
conserved among mammals. (A) Overview of the type III IFN loci in human, 632 
African green monkey, sheep, mouse, and pig. The type III IFN genes illustrated by 633 
different colors share a common synteny in mammals and are flanked on each side by 634 
the leucine rich repeat and fibronectin type III domain containing 1 (LRFN1) and 635 
syncollin (SYCN) genes. Black arrows indicate the direction of transcription for each 636 
gene. (B) HEK293T cells were co-transfected with pGL3.1 plasmid containing the 637 
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IFNL4 or IFNL1/2/3 promoter from human, African green monkey, pig or sheep, a 638 
plasmid constitutively expressing the Renilla luciferase gene and a plasmid 639 
constitutively expressing MAVS. At 24 hours post transfection, firefly/Renilla 640 
luciferase activity was quantified. One representative out of two independent 641 
experiments is shown, each with biological triplicates. The data are presented as 642 
scatter plot with mean ± SD (n=3). (C) HEK293T cells were co-transfected with 643 
pGL3.1 plasmid containing the IFNL4 or IFNL1/2/3 promoter from human, African 644 
green monkey, pig and sheep and a plasmid constitutively expressing the Renilla 645 
luciferase gene. At 24 hours post transfection, the cells were infected with SeV for 646 
another 24 hours before quantifying firefly/Renilla luciferase activity. One 647 
representative out of two independent experiments is shown, each with biological 648 
triplicates. The data are presented as scatter plot with mean ± SD (n=3). Statistical 649 
significance was determined using an unpaired t test. ****; P < 0.0001, ***, 0.0001 < 650 
P < 0.001; **, 0.001 < P < 0.01; *, 0.01 < P < 0.05; ns, P ≥ 0.05. 651 
 652 
Figure 5. Conservation of the IFNL4 promoter among mammals. (A) Alignment 653 
of the proximal/core promoter and the 5’ UTR of IFNL4 from human, African green 654 
monkey, pig and sheep. The transcriptional start site (TSS) as well as putative IRF 655 
and NF-κB binding sites are indicated in the human sequence. (B) Phylogenetic tree 656 
of IFNL1 and IFNL4 from human (H. sapiens), African green monkey (C. sabaeus), 657 
sheep (O. aries), pig (S. scrofa), western European hedgehog (E. europaeus), polar 658 
bear (U. maritimus) based on the sequence of their proximal/core promoter and 5’ 659 
UTR. The sequences were aligned using ClustalW and the tree was generated by the 660 
Neighbor-Joining method. (C) Same as in (B) but using the amino acid sequences of 661 
the proteins instead. Both trees are drawn to scale, with branch lengths measured in 662 
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the number of substitutions per site. 663 
 664 
Figure 6. Insertion of a functional IRF binding site in the IFNL4 promoter 665 
renders it virus-inducible. (A-D) HEK293T cells were co-transfected with a pGL3.1 666 
plasmid containing the IFNL1 or IFNL4 promoter or chimeras thereof, a plasmid 667 
constitutively expressing the Renilla luciferase gene and a plasmid constitutively 668 
expressing MAVS. At 24 hours post transfection, firefly/Renilla luciferase activity 669 
was quantified. One representative out of two independent experiments is shown, 670 
each with biological triplicates. The data are presented as scatter plot with mean ± SD 671 
(n=3). (A) In chimera A and B, the first 100 bp upstream of the TSS has been 672 
swapped between the IFNL1 and IFNL4 promoters as indicated by the colors on the 673 
drawing. (B) In chimera C, the IRF binding site from IFNL1 was inserted into the 674 
IFNL4 promoter at the same relative position it occupied in IFNL1. In chimera C 675 
(mutIRF), the IFNL1 IRF binding site in chimera C was mutated to render it inactive. 676 
(C) In chimera D, the IRF binding site in IFNL1 was replaced with the putative IRF 677 
binding site from IFNL4. In chimera E, the putative IRF binding site in IFNL4 was 678 
replaced with the IRF binding site from IFNL1. (D) In chimera C (mutNF-κB1), the 679 
NF-κB binding site located upstream of the TSS in IFNL4 was mutated to render it 680 
inactive. In chimera C (mutNF-κB2), the NF-κB binding site located downstream of 681 
the TSS in IFNL4 was mutated to render it inactive. In chimera C (mutNF-κB1/2) 682 
both NF-κB binding sites were simultaneous mutated. Statistical significance was 683 
determined using ANOVA and Dunnett’s T3 multiple comparison test. ***, 0.0001 < 684 
P < 0.001; **, 0.001 < P < 0.01; ns, P ≥ 0.05. 685 
 686 
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Figure 7. Recruitment of IRF3 and RNA polymerase II to the IFNL4 and IFNL1 687 
promoters. A549 cells were mock-infected or infected with SeV for 4 hours before 688 
performing ChIP with antibodies against IRF3 (A), RNA polymerase II (B) and IgG 689 
as control (C). One representative out of two independent experiments is shown, each 690 
with biological duplicates. The data are presented as bar chart and scatter plot with 691 
mean. 692 
 693 
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